1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules
(
- Contribution to journal › Article
- 2014
-
Mark
Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re
(
- Contribution to journal › Article
-
Mark
Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates
(
- Contribution to journal › Article
-
Mark
188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors : preclinical assessment
2014) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 55(11). p.8-1842(
- Contribution to journal › Article
- 2013
-
Mark
Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules : comparison with (111)In-labeled counterparts
(
- Contribution to journal › Article
-
Mark
Influence of nuclides and chelators on imaging using affibody molecules : comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA
(
- Contribution to journal › Article
- 2012
-
Mark
Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules
(
- Contribution to journal › Article